Anthony Doyle Net Worth

The estimated Net Worth of Anthony Doyle is at least $2.12 Million dollars as of 14 May 2024. Mr. Doyle owns over 36,300 units of Biocryst Pharmaceuticals stock worth over $2,061,931 and over the last 5 years he sold BCRX stock worth over $62,130. In addition, he makes $0 as Chief Financial Officer and Senior Vice President at Biocryst Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Doyle BCRX stock SEC Form 4 insiders trading

Anthony has made over 4 trades of the Biocryst Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 36,300 units of BCRX stock worth $202,191 on 14 May 2024.

The largest trade he's ever made was buying 54,000 units of Biocryst Pharmaceuticals stock on 11 August 2020 worth over $220,320. On average, Anthony trades about 13,126 units every 137 days since 2020. As of 14 May 2024 he still owns at least 266,744 units of Biocryst Pharmaceuticals stock.

You can see the complete history of Mr. Doyle stock trades at the bottom of the page.

Anthony Doyle biography

Anthony Doyle serves as Chief Financial Officer, Senior Vice President of the Company. He joins the Company from Worldwide Clinical Trials Holdings, Inc. (“WCT”), a full service global contract research organization, where he served as Chief Financial Officer since 2014. From 2004 to 2012, Mr. Doyle held a series of increasingly responsible roles at General Electric, moving through financial planning & analysis, controller, audit, tax and commercial finance rotations in the GE Financial Management and Corporate Audit Staff finance and leadership training programs. He then led risk and pricing for GE Healthcare’s $1.2 billion U.S. diagnostic imaging business and served as global program manager for GE Healthcare Solutions, a hospital and healthcare outcomes-based consulting company. From 2012 to 2014, he was CFO of World Book, a Berkshire Hathaway company. Mr. Doyle completed his Bachelor’s degree from Dublin City University (Ireland) and his DESEM from Reims Management School (France). Mr. Doyle also has a Graduate Certificate in Corporate Treasury from Dublin City University.

How old is Anthony Doyle?

Anthony Doyle is 40, he's been the Chief Financial Officer and Senior Vice President of Biocryst Pharmaceuticals since 2020. There are 21 older and 1 younger executives at Biocryst Pharmaceuticals. The oldest executive at Biocryst Pharmaceuticals Inc. is Robert Ingram, 77, who is the Independent Chairman of the Board.

What's Anthony Doyle's mailing address?

Anthony's mailing address filed with the SEC is 4505 EMPEROR BLVD., SUITE 200, DURHAM, NC, 27703.

Insiders trading at Biocryst Pharmaceuticals

Over the last 24 years, insiders at Biocryst Pharmaceuticals have traded over $76,362,383 worth of Biocryst Pharmaceuticals stock and bought 4,042,003 units worth $20,848,654 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Brothers Life Sciences Capi..., and Carl L Gordon. On average, Biocryst Pharmaceuticals executives and independent directors trade stock every 31 days with the average trade being worth of $542,329. The most recent stock trade was executed by Amy E Mc Kee on 24 June 2024, trading 8,600 units of BCRX stock currently worth $54,352.

What does Biocryst Pharmaceuticals do?

biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.

Complete history of Mr. Doyle stock trades at Biocryst Pharmaceuticals

Biocryst Pharmaceuticals executives and stock owners

Biocryst Pharmaceuticals executives and other stock owners filed with the SEC include:

• Jon Stonehouse,
  President, Chief Executive Officer, Director
• Megan Sniecinski,
  Senior Vice President, Chief Business Officer
• Alane Barnes,
  Senior Vice President, Chief Legal Officer and Corporate Secretary
• Jon P. Stonehouse,
  CEO, Pres & Exec. Director
• Yarlagadda Babu,
  Senior Vice President - Drug Discovery
• William Sheridan,
  Senior Vice President, Chief Medical Officer
• Dr. William P. Sheridan,
  Chief Medical Officer & Sr. VP
• Dr. Yarlagadda S. Babu,
  Chief Discovery Officer
• Stephen Aselage,
  Independent Director
• Robert Ingram,
  Independent Chairman of the Board
• Kenneth Lee,
  Independent Director
• Nancy Hutson,
  Independent Director
• George Abercrombie,
  Independent Director
• Theresa Heggie,
  Independent Director
• Helen Thackray,
  Independent Director
• Dr. Helen M. Thackray FAAP, M.D.,
  Chief R&D Officer
• Anthony Doyle,
  Chief Financial Officer, Senior Vice President
• Alan Levin,
  Independent Director
• Charles Gayer,
  Senior Vice President, Chief Commercial Officer
• Allen Hodge,
  Vice President and General Manager for the United States
• Michael Jones,
  Executive Director - Finance, Principal Accounting Officer
• Alane P. Barnes,
  Sr. VP, Chief Legal Officer & Corp. Sec.
• Michael L. Jones,
  Exec. Director of Fin. & Principal Accounting Officer
• Dr. Elliott T. Berger,
  Sr. VP of Regulatory Affairs
• Robert C. Stoner,
  VP of HR
• John D. Bluth,
  Sr. VP of Investor Relations & Corp. Communications
• Anthony Doyle,
  Sr. VP & CFO
• Sanj K Patel,
  Director
• Stanley C Erck,
  Director
• Fred E Cohen,
  Director
• Lynne Powell,
  Senior VP - CCO
• Thomas R Ii Staab,
  Senior Vice President and CFO
• Bros. Advisors Lp Baker Bro...,
  
• John L Higgins,
  Director
• Felix Baker Bros. Investmen...,
  
• Zola P Horovitz,
  Director
• Robert S Lowrey,
  Controller, PAO
• Steven K Galson,
  Director
• Steve Aselage,
  Director
• Brothers Life Sciences Capi...,
  
• David Mc Cullough,
  VP
• Bros. Capital (Gp), Llcbake...,
  
• Stephen R Biggar,
  Director
• Stuart Grant,
  SR VP & CFO
• Beth C Seidenberg,
  Director
• William W Featheringill,
  Director
• / Tisch Capital (Gp), Llcba...,
  
• Biotech Capital (Gp), Llcba...,
  
• Capital (Gp), Llcbaker Juli...,
  
• Mike Mills,
  Principal Accounting Officer
• Partners L P/Ilbiotechnolog...,
  
• Carl L Gordon,
  Director
• Charles E Bugg,
  CEO
• J Claude Bennett,
  President
• John A Montgomery,
  Director
• Jonathan M Nugent,
  VP Corp Communications
• W James Alexander,
  SR. VP, Chief Medical Officer
• Randall B Riggs,
  VP Business Development
• Michael A Darwin,
  CFO
• Randolph C Steer,
  Director
• Joseph H Jr Sherrill,
  Director
• William M Iii Spencer,
  Director
• Charles A Sanders,
  Director
• Peder Jensen,
  Director
• Amy E Mc Kee,
  Director
• Machelle Sanders,
  Director
• Vincent Milano,
  Director